PMA device
Restylane® Contour
Q-Med AB · Implant, Dermal, For Aesthetic Use (LMH, Class III) · First FDA decision Jun 28, 2021, newest Sep 18, 2026Aesthetic skin, fat and body contouring
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
5
PMA pathway
Device trials
15
Naming "Restylane Contour"
MAUDE reports
36
Brand "Restylane Contour", since 2015
PubMed studies
0
Mentioning "Restylane Contour"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Restylane® Contour
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 5 of 5 decisions filed under this name.
- Restylane® ContourPMA supplement
P140029-S058 · Decided Sep 18, 2026 · 120 days after receipt · Normal 180 Day Track No User Fee
Device type: Implant, dermal, for aesthetic use (LMH) · General & Plastic Surgery
4 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Restylane Contour", any status and sponsor, newest update first.
- Effectiveness and Safety of Restylane Contour in the Treatment of Temple HollowingPivotal-lookingCompleted
Galderma R&DNot on our public-company list
NCT05691972 · 225 participants · Start Mar 14, 2023 · Primary completion Oct 26, 2023
Device: Restylane Contour · For: Temporal Hollowing
Sites: Phoenix, Arizona; Encino, California; Los Angeles, California · 15 sites in all
14 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Restylane Contour", and for the whole product code for context.
This brand
36 reports: 0 malfunction, 36 injury, 0 death
Whole product code LMH
16,542 reports: 1,388 malfunction, 15,105 injury, 12 death
Newest reports for this brand
- RESTYLANE CONTOURInjury
9710154-2026-00066 · Received Aug 14, 2026
Device type: Implant, Dermal, For Aesthetic Use (LMH)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Eye Injury; Unspecified Tissue Injury
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Restylane Contour"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code LMH.
- RADIESSE® Injectable ImplantMerz North America, Inc. · PMA 2026
- SculptraQ-Med AB · PMA 2024
- Belotero Balance Dermal FillerMerz North America, Inc. · PMA 2026
- Restylane Injectable GelQ-Med AB · PMA 2022
- Juvederm Voluma XCAllergan · PMA 2025
- Juvéderm Voluma XC, Vollure XC, Volbella XC, Volux XC, SkinviveAllergan · PMA 2026
- Restylane® Lyft with LidocaineQ-Med AB · PMA 2025
- Belotero Balance (+) Lidocaine Dermal FillerMerz North America, Inc. · PMA 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.